Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer talked about. A caller asked if investors should take advantage ...

Multiple lawsuits have been filed against the makers of the popular weight-loss drug. Litigants cite blindness and other side-effects.

A federal judge has dismissed a proposed class action lawsuit accusing Novo Nordisk Inc. and its fiduciary boards of mismanaging a $1.2 billion ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

Catalent is laying off 350 employees in its gene therapy manufacturing division in Baltimore “due to an unexpected shift in ...